Table 3.
Multivariable Model for the Primary Composite End Point by Increasing HbA1c
| Variable | HR (95% CI) | P Value |
|---|---|---|
| Baseline HbA1c (%) | 1.06 (1.02–1.11) | 0.003 |
| Congestive heart failure | 1.62 (1.40–1.86) | <0.001 |
| Recent acute coronary syndrome | 1.56 (1.35–1.81) | <0.001 |
| Baseline systolic blood pressure, mm Hga | 1.13 (1.08–1.17) | <0.001 |
| Baseline diastolic blood pressure, mm Hga | 0.86 (0.80–0.92) | <0.001 |
| Peripheral artery disease | 1.26 (1.08–1.46) | 0.003 |
| Renal impairment | 1.28 (1.08–1.52) | 0.004 |
| Hypertension | 1.46 (1.13–1.90) | 0.005 |
| Baseline apolipoprotein B (mg/dL)a | 1.03 (1.01–1.06) | 0.012 |
| Current smoker | 1.17 (1.00–1.38) | 0.053 |
| History of stroke | 1.21 (0.99–1.48) | 0.057 |
HbA1c indicates hemoglobin A1c; HR, hazard ratio.
Other variables considered, but not significant, in the final model include age, sex, body mass index, prior myocardial infarction, baseline laboratory values (low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, triglycerides, and apolipoprotein A‐I), and baseline use of antiglycemic medication and high‐intensity statin.
a
HR and 95% CI are given per 10‐unit increase.